{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:49:39Z","timestamp":1772527779476,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T00:00:00Z","timestamp":1539734400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00108-018-0509-z","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T07:28:32Z","timestamp":1539761312000},"page":"1239-1248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Porphyrien \u2013 was ist gesichert?","Porphyrias\u2013what is verified?"],"prefix":"10.1007","volume":"59","author":[{"given":"U.","family":"St\u00f6lzel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Kubisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Stauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,17]]},"reference":[{"key":"509_CR1","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1056\/NEJM198409063111006","volume":"311","author":"KE Anderson","year":"1984","unstructured":"Anderson KE, Spitz IM, Sassa S et al (1984) Prevention of cyclical attacks of acute intermittent porphyria with a\u00a0long-acting agonist of luteinizing hormone-releasing hormone. N\u00a0Engl J Med 311:643\u2013645. \n                    https:\/\/doi.org\/10.1056\/NEJM198409063111006","journal-title":"N Engl J Med"},{"key":"509_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29313","author":"M Balwani","year":"2017","unstructured":"Balwani M, Wang B, Anderson KE et\u00a0al (2017) Acute hepatic Porphyrias: recommendations for evaluation and long term management. Hepatology. \n                    https:\/\/doi.org\/10.1002\/hep.29313","journal-title":"Hepatology"},{"key":"509_CR3","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1056\/NEJMra1608634","volume":"377","author":"DM Bissell","year":"2017","unstructured":"Bissell DM, Anderson KE, Bonkovsky HL (2017) Porphyria. N\u00a0Engl J Med 377:862\u2013872. \n                    https:\/\/doi.org\/10.1056\/NEJMra1608634","journal-title":"N Engl J Med"},{"key":"509_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-40337-8","volume-title":"Physician\u2019s guide to the diagnosis, treatment, and follow-up of inherited metabolic diseases","author":"N Blau","year":"2014","unstructured":"Blau N, Duran M, Gibson KM, Dionisi-Vici C (2014) Physician\u2019s guide to the diagnosis, treatment, and follow-up of inherited metabolic diseases. Springer, Berlin Heidelberg"},{"key":"509_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c120006","author":"HL Bonkovsky","year":"2013","unstructured":"Bonkovsky HL, Guo J\u2011T, Hou W et al (2013) Porphyrin and heme metabolism and the Porphyrias. Compr Physiol. \n                    https:\/\/doi.org\/10.1002\/cphy.c120006","journal-title":"Compr Physiol"},{"key":"509_CR6","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20130045","author":"HJ Bustad","year":"2013","unstructured":"Bustad HJ, Vorland M, R\u00f8nneseth E et\u00a0al (2013) Conformational stability and activity analysis of two hydroxymethylbilane synthase mutants, K132N and V215E, with different phenotypic association with acute intermittent porphyria. Biosci Rep. \n                    https:\/\/doi.org\/10.1042\/BSR20130045","journal-title":"Biosci Rep"},{"key":"509_CR7","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1038\/mtna.2015.36","volume":"4","author":"A Chan","year":"2015","unstructured":"Chan A, Liebow A, Yasuda M et\u00a0al (2015) Preclinical development of a\u00a0subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic Porphyrias using circulating RNA Quantification. Mol Ther Nucleic Acids 4:e263. \n                    https:\/\/doi.org\/10.1038\/mtna.2015.36","journal-title":"Mol Ther Nucleic Acids"},{"key":"509_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15502","author":"A Combalia","year":"2017","unstructured":"Combalia A, To-Figueras J, Laguno M et al (2017) Direct-acting antivirals for hepatitis C virus induce a\u00a0rapid clinical and biochemical remission of porphyria cutanea tarda. Br J Dermatol. \n                    https:\/\/doi.org\/10.1111\/bjd.15502","journal-title":"Br J Dermatol"},{"key":"509_CR9","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/hep.1840160603","volume":"16","author":"S Fargion","year":"1992","unstructured":"Fargion S, Piperno A, Cappellini MD et\u00a0al (1992) Hepatitis C virus and porphyria cutanea tarda: evidence of a\u00a0strong association. Hepatology 16:1322\u20131326","journal-title":"Hepatology"},{"key":"509_CR10","doi-asserted-by":"publisher","first-page":"39392","DOI":"10.1074\/jbc.M306148200","volume":"278","author":"DJ Fraser","year":"2003","unstructured":"Fraser DJ, Zumsteg A, Meyer UA (2003) Nuclear receptors constitutive Androstane receptor and Pregnane X receptor activate a\u00a0drug-responsive enhancer of the murine 5\u2011Aminolevulinic acid Synthase gene. J\u00a0Biol Chem 278:39392\u201339401. \n                    https:\/\/doi.org\/10.1074\/jbc.M306148200","journal-title":"J Biol Chem"},{"key":"509_CR11","first-page":"89","volume":"105","author":"H G\u00fcnther","year":"1911","unstructured":"G\u00fcnther H (1911) Die H\u00e4matoporphyrie. Dtsch Arch Klin Med 105:89\u2013146","journal-title":"Dtsch Arch Klin Med"},{"key":"509_CR12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.cell.2005.06.040","volume":"122","author":"C Handschin","year":"2005","unstructured":"Handschin C, Lin J, Rhee J et al (2005) Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell 122:505\u2013515. \n                    https:\/\/doi.org\/10.1016\/j.cell.2005.06.040","journal-title":"Cell"},{"key":"509_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10545-010-9237-9","volume":"34","author":"A Hasanoglu","year":"2011","unstructured":"Hasanoglu A, Balwani M, Kasapkara CS et\u00a0al (2011) Harderoporphyria due to homozygosity for coproporphyrinogen oxidase missense mutation H327R. J\u00a0Inherit Metab Dis 34:225\u2013231. \n                    https:\/\/doi.org\/10.1007\/s10545-010-9237-9","journal-title":"J Inherit Metab Dis"},{"key":"509_CR14","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/bjh.13612","volume":"173","author":"C Landefeld","year":"2016","unstructured":"Landefeld C, Kentouche K, Gruhn B et al (2016) X\u2011linked protoporphyria: Iron supplementation improves protoporphyrin overload, liver damage and anaemia. Br J Haematol 173:482\u2013484. \n                    https:\/\/doi.org\/10.1111\/bjh.13612","journal-title":"Br J Haematol"},{"key":"509_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1056\/NEJMoa1411481","volume":"373","author":"JG Langendonk","year":"2015","unstructured":"Langendonk JG, Balwani M, Anderson KE et\u00a0al (2015) Afamelanotide for Erythropoietic Protoporphyria. N\u00a0Engl J Med 373:48\u201359. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1411481","journal-title":"N Engl J Med"},{"key":"509_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy030","author":"H Lenglet","year":"2018","unstructured":"Lenglet H, Schmitt C, Grange T et\u00a0al (2018) From a\u00a0dominant to an oligogenic model of inheritance with environmental modifiers in Acute Intermittent Porphyria. Hum Mol Genet. \n                    https:\/\/doi.org\/10.1093\/hmg\/ddy030","journal-title":"Hum Mol Genet"},{"key":"509_CR17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/jclinpath-2012-201367","volume":"67","author":"JT Marsden","year":"2014","unstructured":"Marsden JT, Rees DC (2014) Urinary excretion of porphyrins, porphobilinogen and \u03b4\u2011aminolaevulinic acid following an attack of acute intermittent porphyria. J\u00a0Clin Pathol 67:60\u201365. \n                    https:\/\/doi.org\/10.1136\/jclinpath-2012-201367","journal-title":"J Clin Pathol"},{"key":"509_CR18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/archderm.139.3.379","volume":"139","author":"JM Mascaro","year":"2003","unstructured":"Mascaro JM, Herrero C (2003) New reasons for an archaic treatment: phlebotomy in sporadic porphyria cutanea tarda. Arch Dermatol 139:379\u2013380","journal-title":"Arch Dermatol"},{"key":"509_CR19","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1172\/JCI116348","volume":"91","author":"P Meissner","year":"1993","unstructured":"Meissner P, Adams P, Kirsch R (1993) Allosteric inhibition of human lymphoblast and purified porphobilinogen deaminase by protoporphyrinogen and coproporphyrinogen. A possible mechanism for the acute attack of variegate porphyria. J\u00a0Clin Invest 91:1436\u20131444","journal-title":"J Clin Invest"},{"key":"509_CR20","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1001\/archinte.1993.00410170078008","volume":"153","author":"P Mustajoki","year":"1993","unstructured":"Mustajoki P, Nordmann Y (1993) Early administration of heme arginate for acute porphyric attacks. Arch Intern Med 153:2004\u20132008","journal-title":"Arch Intern Med"},{"key":"509_CR21","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1172\/JCI111039","volume":"72","author":"Y Nordmann","year":"1983","unstructured":"Nordmann Y, Grandchamp B, de Verneuil H et\u00a0al (1983) Harderoporphyria: a\u00a0variant hereditary coproporphyria. J\u00a0Clin Invest 72:1139\u20131149. \n                    https:\/\/doi.org\/10.1172\/JCI111039","journal-title":"J Clin Invest"},{"key":"509_CR22","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.1073\/pnas.0700547104","volume":"104","author":"JD Phillips","year":"2007","unstructured":"Phillips JD, Bergonia HA, Reilly CA et\u00a0al (2007) A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci Usa 104:5079\u20135084. \n                    https:\/\/doi.org\/10.1073\/pnas.0700547104","journal-title":"Proc Natl Acad Sci Usa"},{"key":"509_CR23","doi-asserted-by":"publisher","first-page":"9127","DOI":"10.1073\/pnas.0401845101","volume":"101","author":"M Podvinec","year":"2004","unstructured":"Podvinec M, Handschin C, Looser R, Meyer UA (2004) Identification of the xenosensors regulating human 5\u2011aminolevulinate synthase. Proc Natl Acad Sci Usa 101:9127\u20139132. \n                    https:\/\/doi.org\/10.1073\/pnas.0401845101","journal-title":"Proc Natl Acad Sci Usa"},{"key":"509_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16741","author":"H Salameh","year":"2018","unstructured":"Salameh H, Sarairah H, Rizwan M et al (2018) Relapse of porphyria cutanea tarda after treatment with phlebotomy or 4\u2011aminoquinoline antimalarial: a meta-analysis. Br J Dermatol. \n                    https:\/\/doi.org\/10.1111\/bjd.16741","journal-title":"Br J Dermatol"},{"key":"509_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12750","author":"C Schmitt","year":"2018","unstructured":"Schmitt C, Lenglet H, Yu A et\u00a0al (2018) Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver. J\u00a0Intern Med. \n                    https:\/\/doi.org\/10.1111\/joim.12750","journal-title":"J Intern Med"},{"key":"509_CR26","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/hep.27086","volume":"60","author":"AK Singal","year":"2014","unstructured":"Singal AK, Parker C, Bowden C et\u00a0al (2014) Liver transplantation in the management of Porphyria. Hepatology 60:1082\u20131089. \n                    https:\/\/doi.org\/10.1002\/hep.27086","journal-title":"Hepatology"},{"key":"509_CR27","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1002\/hep.1840210604","volume":"21","author":"U St\u00f6lzel","year":"1995","unstructured":"St\u00f6lzel U, K\u00f6stler E, Koszka C et\u00a0al (1995) Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. Hepatology 21:1500\u20131503","journal-title":"Hepatology"},{"key":"509_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/archderm.139.3.309","volume":"139","author":"U St\u00f6lzel","year":"2003","unstructured":"St\u00f6lzel U, K\u00f6stler E, Schuppan D et\u00a0al (2003) Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. Arch Dermatol 139:309\u2013313","journal-title":"Arch Dermatol"},{"key":"509_CR29","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ajhg.2008.08.003","volume":"83","author":"SD Whatley","year":"2008","unstructured":"Whatley SD, Ducamp S, Gouya L et al (2008) C\u2011terminal deletions in the ALAS2 gene lead to gain of function and cause X\u2011linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 83:408\u2013414. \n                    https:\/\/doi.org\/10.1016\/j.ajhg.2008.08.003","journal-title":"Am J Hum Genet"},{"key":"509_CR30","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/j.1365-4632.2009.04205.x","volume":"48","author":"U Wollina","year":"2009","unstructured":"Wollina U, K\u00f6stler E, Koch A et\u00a0al (2009) Does chloroquine therapy of porphyria cutanea tarda influence liver pathology? Int J Dermatol 48:1250\u20131253. \n                    https:\/\/doi.org\/10.1111\/j.1365-4632.2009.04205.x","journal-title":"Int J Dermatol"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-018-0509-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0509-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0509-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T23:17:44Z","timestamp":1571267864000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-018-0509-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,17]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["509"],"URL":"https:\/\/doi.org\/10.1007\/s00108-018-0509-z","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,17]]},"assertion":[{"value":"17 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"U.\u00a0St\u00f6lzel und T.\u00a0Stauch haben Vortragshonorare und Reisekosten von Orphan Europe erhalten, die jedoch nicht in direktem Zusammenhang mit der vorliegenden Publikation stehen. I.\u00a0Kubisch gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}